
Pharmacally
Opzelura
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Opzelura
Clinical TrialsIncyte Shows Durable 24-Week Response With Opzelura in Moderate ADFinal 24-week results from the Phase 3 TRuE-AD4 study showed durable disease control with Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis, with 84.3% of patients achieving…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.